URGO FilmoCream Eczema cream used with steroid cream for atopic dermatitis
Tests a moisturizing cream added to steroid cream on eczema lesions in adults.
Plain-language title generated from the registry record
Registry title: URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis
Key facts
- Where
- Gdansk and Malbork, PolandSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with mild to moderate atopic dermatitis who have two similar eczema lesions needing corticosteroid cream. One lesion gets the steroid cream alone, the other gets it with URGO FilmoCream Eczema.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Mild to moderate atopic dermatitis (by the Investigator's Global Assessment for Atopic Dermatitis, IGA-AD), with two comparable lesions at anatomically distant sites that need topical corticosteroids.
- Earlier treatment
- No systemic treatment (including oral corticosteroids) or topical treatment on the tested area that the investigator finds likely to interfere with the study, in the weeks before inclusion.
Main reasons for not taking part
- Known contraindication to topical corticosteroids, such as hypersensitivity to desonide or betamethasone
- Broken or ulcerated skin, acne, rosacea, active skin infection or skin thinning at the application sites
- Pregnant, breastfeeding or planning pregnancy during the study
- Ongoing treatment or illness that the investigator thinks could interfere with the study
- Taking part in another clinical study that may interfere
Read by machine on 9 November 2026.
Where in Poland
- Eurofins Dermscan PolandGdansk, PolandNo longer taking part
- Private PracticeMalbork, PolandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- CEN Biotech
- Trial code
- NCT07295678
- Record updated
- 26 December 2025
- Original description
The goal of this clinical study is to determine whether URGO FilmoCream Eczema is effective as a non-steroidal treatment to relieve symptoms of atopic dermatitis. It also aims to evaluate the cream's ability to moisturize, soothe irritation, protect the skin, and promote healing of eczema lesions. The main questions the study seeks to answer are:Read full original descriptionShow less
Open-label Clinical Investigation to Evaluate the Performance and Safety of Medical Device "Urgo Filmocream Eczema" in Association With Dermocorticoids on Atopic Dermatitis Lesions
The goal of this clinical study is to determine whether URGO FilmoCream Eczema is effective as a non-steroidal treatment to relieve symptoms of atopic dermatitis. It also aims to evaluate the cream's ability to moisturize, soothe irritation, protect the skin, and promote healing of eczema lesions. The main questions the study seeks to answer are:
1. Does URGO FilmoCream Eczema improve symptom relief of atopic dermatitis when used alongside standard topical corticosteroid treatment? 2. How do eczema lesions treated with topical corticosteroids alone progress and heal compared to those treated with topical corticosteroids plus URGO FilmoCream Eczema? To investigate this, patients with at least two similar eczema lesions are enrolled. One lesion is treated with topical corticosteroids alone, while the other is treated with topical corticosteroids plus URGO FilmoCream Eczema.
The progression of both lesions is monitored throughout treatment, until healing, and for 28 days after the last application of topical corticosteroids.
Inclusion: Male or female subject; Aged 18 or more; With mild to moderate atopic dermatitis based on the Investigator's Global Assessment for Atopic Dermatitis (IGA-AD); Presence of two comparable atopic dermatitis lesions requiring treatment with topical corticosteroids, located at anatomically distant sites; Having given her/his informed, written consent,; Cooperative, fully informed of the treatment procedures, and aware of the importance and schedule of follow-up visits, ensuring expected full adherence to the study protocol; Psychologically capable of understanding the study information and providing informed consent; Affiliated to a health social security system; Female of childbearing potential should use a contraceptive regimen recognized as effective since at least 12 weeks before screening visit, during all the study and at least 1 month after the study end and must have a negative urine pregnancy test before the first treatment.
Exclusion: Any systemic treatment, including oral corticosteroids, that is incompatible with the study or likely to interfere with study assessments according to the investigator, administered in the weeks prior to the inclusion visit, ongoing, or planned to start during the study; Any topical treatment on the tested area that is incompatible with the study or likely to interfere with study assessments according to the investigator, administered in the weeks prior to the inclusion visit; Subject unable to understand the information provided - including study procedures - due to linguistic or psychiatric reasons, and therefore unable to give written informed consent or to complete the study diary as required; Subject with a known contraindication to topical corticosteroids, such as hypersensitivity to desonide, betamethasone, or any component of the prescribed corticosteroid formulations; Subject with broken or ulcerated skin, acne, rosacea (including perioral dermatitis), any untreated or active skin infection (viral, bacterial, or fungal), or skin thinning at the application sites; Subject with a skin disease, abnormality, or dermatological condition in the study area that may interfere with study assessments; Subject with acute, chronic, or progressive disease, or relevant medical history, considered by the investigator to be hazardous for the subject, incompatible with the study, or likely to interfere with study assessments; Subject currently participating in another clinical study that may interfere with the assessments of the present study, according to the investigator's judgment; Subject who, in the investigator's judgment, is unlikely to comply with study-related constraints and requirements; Subject who has forfeited his/her freedom by administrative or legal decision, or who is under legal guardianship; Female subject of childbearing potential who is pregnant, breastfeeding, or planning to become pregnant during the study.